Banana Lectin: A Novel Immunomodulatory Strategy for Mitigating Inflammatory Bowel Disease

Author:

Miljkovic Radmila1ORCID,Marinkovic Emilija1,Lukic Ivana1ORCID,Kovacevic Ana1,Lopandic Zorana2ORCID,Popovic Mina3,Gavrovic-Jankulovic Marija4ORCID,Schabussova Irma5,Inic-Kanada Aleksandra5ORCID,Stojanovic Marijana6ORCID

Affiliation:

1. Department of Research and Development, Institute of Immunology, Virology, Vaccines and Sera—Torlak, 11152 Belgrade, Serbia

2. Institute for Chemistry in Medicine, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia

3. Faculty of Ecology and Environmental Protection, University Union—Nikola Tesla, 11158 Belgrade, Serbia

4. Department of Biochemistry, Faculty of Chemistry, University of Belgrade, 11158 Belgrade, Serbia

5. Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria

6. Department of Molecular Biology, Institute for Biological Research “Siniša Stanković”—National Institute of the Republic of Serbia, University of Belgrade, 11108 Belgrade, Serbia

Abstract

Compared to the general population, patients with inflammatory bowel disease (IBD) are less likely to be vaccinated, putting them at an increased risk of vaccine-preventable illnesses. This risk is further compounded by the immunosuppressive therapies commonly used in IBD management. Therefore, developing new treatments for IBD that maintain immune function is crucial, as successful management can lead to better vaccination outcomes and overall health for these patients. Here, we investigate the potential of recombinant banana lectin (rBanLec) as a supporting therapeutic measure to improve IBD control and possibly increase vaccination rates among IBD patients. By examining the therapeutic efficacy of rBanLec in a murine model of experimental colitis, we aim to lay the foundation for its application in improving vaccination outcomes. After inducing experimental colitis in C57BL/6 and BALB/c mice with 2,4,6-trinitrobenzene sulfonic acid, we treated animals orally with varying doses of rBanLec 0.1–10 µg/mL (0.01—1 µg/dose) during the course of the disease. We assessed the severity of colitis and rBanLec’s modulation of the immune response compared to control groups. rBanLec administration resulted in an inverse dose–response reduction in colitis severity (less pronounced weight loss, less shortening of the colon) and an improved recovery profile, highlighting its therapeutic potential. Notably, rBanLec-treated mice exhibited significant modulation of the immune response, favoring anti-inflammatory pathways (primarily reduction in a local [TNFα]/[IL-10]) crucial for effective vaccination. Our findings suggest that rBanLec could mitigate the adverse effects of immunosuppressive therapy on vaccine responsiveness in IBD patients. By improving the underlying immune response, rBanLec may increase the efficacy of vaccinations, offering a dual benefit of disease management and prevention of vaccine-preventable illnesses. Further studies are required to translate these findings into clinical practice.

Funder

Ministry of Science, Technological Development and Innovation, Republic of Serbia

Austrian Science Fund

OEAD

Publisher

MDPI AG

Reference37 articles.

1. The global burden of IBD: From 2015 to 2025;Kaplan;Nat. Rev. Gastroenterol. Hepatol.,2015

2. Extraintestinal manifestations of inflammatory bowel disease;Levine;Gastroenterol. Hepatol.,2011

3. Nutritional concerns in pediatric inflammatory bowel disease patients;Kappelman;Mol. Nutr. Food Res.,2008

4. Vaccinating Patients with Inflammatory Bowel Disease;Reich;Gastroenterol. Hepatol.,2016

5. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments;Garcia;Mediat. Inflamm.,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3